Uthman Okikiola Adebayo

Mr. Uthman Okikiola Adebayo

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2025 in Healthcare
Verified
Journal Article
Open access
PDF file
MAMohamed Mustaf Ahmed
Mohamed Mustaf Ahmed
Okesanya John OlalekanOkesanya John Olalekan
Okesanya John Olalekan
NONoah Olabode Olaleke
Noah Olabode Olaleke
Olaniyi Abideen AdigunOlaniyi Abideen Adigun
Olaniyi Abideen Adigun
Uthman Okikiola AdebayoUthman Okikiola Adebayo
Uthman Okikiola Adebayo
DIDon Eliseo Lucero-Prisno III
Don Eliseo Lucero-Prisno III
Digital health innovations are reshaping global healthcare systems by enhancing access, efficiency, and quality of care. Technologies such as artificial intelligence, telemedicine, mobile health applications, and big data analytics have been widely applied to support disease surveillance, enable remote care, and improve clinical decision making. This review critically identifies persistent implementation challenges that hinder the equitable adoption of digital health solutions, such as the digital divide, limited infrastructure, and weak data governance, particularly in low- and middle-income countries (LMICs). It aims to propose strategic pathways for integrating digital innovations to strengthen universal health coverage (UHC) and bridge health disparities in the region. By analyzing the best global practices and emerging innovations, this study contributes to the ongoing dialogue on leveraging digital health for inclusive, scalable, and sustainable healthcare delivery in underserved regions.

25 November 2025 in Patient Safety in Surgery
Verified
Journal Article
Open access
PDF file
MAMohamed Mustaf Ahmed
Mohamed Mustaf Ahmed
ZOZhinya Kawa Othman
Zhinya Kawa Othman
Uthman Okikiola AdebayoUthman Okikiola Adebayo
Uthman Okikiola Adebayo
OKOmar Kasimieh
Omar Kasimieh
Okesanya John OlalekanOkesanya John Olalekan
Okesanya John Olalekan
DIDon Eliseo Lucero-Prisno III
Don Eliseo Lucero-Prisno III
Artificial intelligence (AI) and machine learning (ML) are increasingly being used in surgical care; however, their real-world impact on patient safety is not well established. This narrative review searched PubMed, Scopus, and Google Scholar for English-language studies published from January 1, 2015, to April 30, 2025, that evaluated AI and ML applications in complex surgery and reported quantitative patient safety outcomes. Eligible included studies were published between 2016 and 2025. In total, 21 studies were synthesized across the preoperative, intraoperative, and postoperative phases of the study. Preoperatively, ML models consistently outperformed traditional risk scores in identifying high-risk patients and anticipating technical difficulties. Intraoperatively, AI-enabled decision support reduced hypotension exposure in a randomized trial, and computer vision systems supported the safety-critical step verification and instrument tracking. Postoperatively, multimodal approaches combining electronic records, imaging, and smartphone wound photographs predicted complications, such as surgical site infection, and facilitated discharge planning. Emerging evidence from ambulatory surgery, imaging-guided triage, and specialty domains, alongside qualitative studies on workforce readiness, highlights implementation opportunities and human factor requirements. Most evidence is retrospective, single-center, or prototype stage with limited external validation and uncertain generalizability across settings, including low- and middle-income countries. Priorities include multicenter prospective trials, standardized outcomes and reporting, continuous bias and model drift monitoring, robust data infrastructure, and equity-focused implementation to translate algorithmic performance into fewer complications, deaths, and costs.

9 September 2025 in Next Bioengineering
Verified
Journal Article
Open access
DIDon Eliseo Lucero-Prisno III
Don Eliseo Lucero-Prisno III
Okesanya John OlalekanOkesanya John Olalekan
Okesanya John Olalekan
AAAbdulmajeed Opeyemi Agboola
Abdulmajeed Opeyemi Agboola
Uthman Okikiola AdebayoUthman Okikiola Adebayo
Uthman Okikiola Adebayo
Olaniyi Abideen AdigunOlaniyi Abideen Adigun
Olaniyi Abideen Adigun
DODavid Bamidele Olawade
David Bamidele Olawade

31 October 2025 in Next Nanotechnology
Verified
Journal Article
Open access
TOTolutope Adebimpe Oso
Tolutope Adebimpe Oso
Uthman Okikiola AdebayoUthman Okikiola Adebayo
Uthman Okikiola Adebayo
OOOlalekan John Okesanya
Olalekan John Okesanya
CCClement Ngele Chukwu
Clement Ngele Chukwu
OAOluwatobi Babajide Ayelaagbe
Oluwatobi Babajide Ayelaagbe
DIDon Eliseo Lucero-Prisno Iii
Don Eliseo Lucero-Prisno Iii

29 December 2025 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
TOTolutope Adebimpe Oso
Tolutope Adebimpe Oso
MAMohamed Mustaf Ahmed
Mohamed Mustaf Ahmed
Okesanya John OlalekanOkesanya John Olalekan
Okesanya John Olalekan
Uthman Okikiola AdebayoUthman Okikiola Adebayo
Uthman Okikiola Adebayo
KOKhalifat Boluwatife Obadeyi
Khalifat Boluwatife Obadeyi
DLDon Eliseo Lucero-Prisno
Don Eliseo Lucero-Prisno
Alzheimer's disease (AD), a progressive neurodegenerative disorder, is increasingly understood as a multifactorial condition influenced by systemic and environmental factors beyond the central nervous system. A growing body of evidence shows that the gut-brain-microbiome axis (GBMA), a complex bidirectional communication network, is involved in neural, endocrine, immune, and metabolic pathways in AD pathogenesis. This narrative review synthesizes emerging insights into the role of gut microbiota dysbiosis in promoting neuroinflammation, amyloid-β aggregation, blood-brain barrier disruption, and cognitive decline. We explored recent advancements in metagenomics and metabolomics for profiling microbial communities and their functional metabolites linked to AD. Alterations in microbe-derived compounds, such as short-chain fatty acids and tryptophan metabolites, influence neurodevelopment, glial activation, and mitochondrial dysfunction. Multi-omics integration, enhanced by artificial intelligence (AI), enables precise biomarker discovery, patient stratification, and the development of personalized therapeutic strategies. Translational opportunities include microbiome-based diagnostics, probiotic therapy, and stratified interventions. However, clinical translation faces challenges such as methodological heterogeneity, inter-individual microbiome variation, data governance issues, and algorithmic bias. We emphasize the need for diverse reference panels, longitudinal multimodal cohorts, and shared AI-ready datasets to enhance the reproducibility and global equity of research. Strategic investment in integrative, ethically governed, and interdisciplinary approaches is essential to unlock the full therapeutic and diagnostic potential of GBMA in AD.

18 November 2025 in Exploration of digital health technologies
Verified
Journal Article
Open access
PDF file
Okesanya John OlalekanOkesanya John Olalekan
Okesanya John Olalekan
Uthman Okikiola AdebayoUthman Okikiola Adebayo
Uthman Okikiola Adebayo
INIfeanyi Ngwoke
Ifeanyi Ngwoke
AAAbdulmajeed Opeyemi Agboola
Abdulmajeed Opeyemi Agboola
FAFaith Ayobami Atewologun
Faith Ayobami Atewologun
DIDon Eliseo Lucero-Prisno III
Don Eliseo Lucero-Prisno III
The integration of artificial intelligence (AI) into psychiatric care is rapidly revolutionizing diagnosis, risk stratification, therapy customization, and the delivery of mental health services. This narrative review synthesized recent research on ethical issues, methodological challenges, and practical applications of AI in psychiatry. A comprehensive literature search was conducted with no limitation to publication year using PubMed, Scopus, Web of Science, and Google Scholar to identify peer-reviewed articles and grey literature related to the integration of AI in psychiatry. AI enhances early identification, predicts relapses and treatment resistance, and facilitates precision pharmacopsychiatry by leveraging data from machine learning, natural language processing, digital phenotyping, and multimodal data integration. This review highlights the advancements in the integration of AI in psychiatric care, such as chatbot-mediated psychotherapy, reinforcement learning for clinical decision-making, and AI-driven triage systems in resource-constrained environments. However, there are still serious concerns about data privacy, algorithmic bias, informed consent, and the interpretability of AI systems. Other barriers to fair and safe implementation include discrepancies in training datasets, underrepresentation of marginalized groups, and a lack of clinician preparedness. There is a need for transparent, explainable, and ethically regulated AI systems that enhance, rather than replace, human decision-making. A hybrid human-AI approach to psychiatry is recommended to address these limitations, while interdisciplinary studies, strong validation frameworks, and inclusive policymaking are needed to guarantee that AI-enhanced mental health treatment continues to be effective, fair, and reliable.